People: MEI Pharma Inc (MEIP.PH)

Summary

Name	Age	Since	Current Position
Daniel Gold	58	2010	President, Chief Executive Officer, Director
Thomas Zech	61	2010	Chief Financial Officer, Secretary
Robert Mass	58	2011	Chief Medical Officer
Christine White	60	2013	Lead Independent Director
Charles Baltic	52	2011	Independent Director
Leah Cann	53	2009	Independent Director
Thomas Reynolds	53	2012	Independent Director
William Rueckert	59	2011	Independent Director
Pete De Spain			Senior Director - Investor Relations & Corporate Communications

» Insider Trading

Biographies

Name	Description
Daniel Gold	Dr. Daniel P. Gold, Ph.D. is President, Chief Executive Officer, Director of MEI Pharma, Inc. From October 2009 to April 2010, Dr. Gold was Managing Partner of Theragence, Inc., which he co-founded. From July 2008 to May 2009, Dr. Gold was President and Chief Executive Officer of Prospect Therapeutics, a clinical stage, oncology focused biotechnology company. From January 2000 to May 2009, Dr. Gold was Chief Scientific Officer of Favrille, Inc., which he founded. Dr. Gold currently serves on the Board of Trustees of the Hope Funds for Cancer Research. Dr. Gold was a member of the Executive Council of the Sabin Cancer Vaccine Consortium from 2004 to 2006 and a member of the board of directors of the San Diego chapter of the Leukemia and Lymphoma Society from 1998 to 2003. Dr. Gold received a Bachelor’s degree in biology from University of California Los Angeles and received a Doctorate degree from Tufts University in Pathology/Immunology.
Thomas Zech	Mr. Thomas M. Zech is Chief Financial Officer of MEI Pharma, Inc. From May 2009 to June 2010, Mr. Zech was a consultant, providing finance and accounting advisory services to life science and technology companies. Until November 2008, Mr. Zech served as Vice President, Finance and Chief Financial Officer at Pacira Pharmaceuticals Inc., a specialty pharmaceutical company, which was the successor company to SkyePharma Inc. acquired in March 2007, from SkyePharma PLC. He transitioned to Pacira Pharmaceuticals from SkyePharma Inc., where he joined in 1999 as Controller and Corporate Secretary. Previously he held senior finance positions at Stratagene, Advanced Tissue Sciences, Allied Holdings and Psicor. Mr. Zech earned his bachelor’s degree in accounting from Lawrence Technological University and his MBA with a concentration in finance from the University of Detroit.
Robert Mass	Dr. Robert D. Mass, M.D., is Chief Medical Officer of MEI Pharma, Inc. Dr. Mass has more than 20 years of experience as a medical oncologist in both clinical practice and clinical drug development. He held a number of leadership positions at Genentech from 1998 to 2009, most recently as Head of Medical Affairs, BioOncology, a position created to strategically integrate and optimize all of the non-sponsored clinical programs within the company’s oncology portfolio. He also served on the Executive Development Review Committee at Genentech, which was responsible for the review and approval of all sponsored clinical programs across the company’s therapeutic portfolio. Previously he served as clinical science leader for Herceptin from 1999 to 2002, Tarceva from 2002 to 2003, and Avastin, currently the oncology therapeutic worldwide, from 2003 to 2007. Prior to joining Genentech, he practiced Hematology and Medical Oncology from 1988 to 1998. After leaving Genentech, Dr. Mass served as a consultant for several oncology companies, including, since October 2010, Marshall Edwards. Dr. Mass earned his bachelor’s degree in economics from Tufts University and his medical degree from Oregon Health & Science University. He completed his residency training in Internal Medicine and a fellowship in Hematology and Medical Oncology at the University of California-San Francisco and is certified by the American Board of Internal Medicine in both Internal Medicine and Medical Oncology.
Christine White	Dr. Christine A. White, M.D., has been appointed as Lead Independent Director of Mei Pharma Inc., effective March 26, 2013. Dr. White served in various senior positions with Biogen Idec from 1996 to 2005, most recently as Senior Vice President, Global Medical Affairs, where she played a role in the development, and commercialization of oncology drugs Rituxan® and Zevalin® and oversaw Oncology, Neurology and Dermatology Global Medical Affairs. Previously, she served as the Director of Clinical Oncology Research at the Sidney Kimmel Cancer Center in San Diego from 1994 to 1996, and was a clinical oncologist and Medical Director of Oncology Research at Scripps Memorial Hospitals in La Jolla and Encinitas, California, from 1984 to 1995, most recently as Chairman, Department of Medicine. Dr. White serves as a member of the board of directors of Arena Pharmaceuticals, a clinical-stage pharmaceutical company. Within the past five years, Dr. White also served as a member of the board of directors of Genoptix Inc., a medical diagnostics company, until its acquisition by Novartis, Monogram Biosciences, a life sciences company, until its acquisition by LabCorp, and Pharmacyclics, a pharmaceutical company. Dr. White serves as on the Scientific Advisory Board of Areva Med LLC. She earned her B.A. in Biology and M.D. from the University of Chicago and is Board certified in both Internal Medicine and Medical Oncology.
Charles Baltic	Mr. Charles V. Baltic, III, is Independent Director of Mei Pharma Inc. Mr. Baltic has been a Managing Director and Co-Head of Healthcare at Needham & Company LLC since 2009. Prior to joining Needham, Mr. Baltic was a Managing Director and head of the biotechnology practice at CRT Capital Group from 2006 to 2008. From 2001 to 2006, he served as a Managing Director in Healthcare Investment Banking at Wachovia Securities. Prior to Wachovia, he was with Healthcare Investment Banking at Cowen and Company for six years, ultimately serving as a Director in life sciences. Prior to beginning his investment banking career in 1996, Mr. Baltic practiced corporate and securities law with Dewey Ballantine, representing numerous healthcare and securities clients. Mr. Baltic earned his B.A and J.D. degrees from Georgetown University and an M.B.A. degree in finance from the Wharton School of the University of Pennsylvania. Mr. Baltic is also a founding Trustee and past Chair of the Development Committee and current Chair of the Programs Committee of the non-profit Hope Funds for Cancer Research. Mr. Baltic is a former Director of MedVantage Inc., which was acquired by Blues Plans Inc., a consortium of the Blues Plans of Massachusetts, North Carolina, Florida, Arkansas and Illinois.
Leah Cann	Ms. Leah Rush Cann is Independent Director of MEI Pharma, Inc. She also serves as chairperson of the Audit Committee since March 2009. Ms. Cann is the President of Leah Rush Cann Research and Consulting, LLC, a cancer –consulting organization which she founded in 2003. She was a research scientist with Memtec Corporation from 1984 to 1986. Ms. Cann was a research analyst with CIBC Oppenheimer from 1992 to 1999. From 1999 to 2000, she was a health care analyst with Cadence Capital, an asset manager based in Boston, Massachusetts. Ms. Cann was a senior biotechnology analyst with Wachovia Securities from 2000 to 2003. In both 1995 and 1996, The Wall Street Journal recognized Ms. Cann as an All-Star analyst. Ms. Cann received a B.A. in art history and chemistry and an M.B.A from Stetson University. She was a post-baccalaureate at the College of William and Mary and a post-graduate at Columbia University. Ms. Cann has been a trustee and member of several committees of International House in New York City for more than 10 years. She is a trustee and the chairman of the Executive Committee of the Hope Funds for Cancer Research, which she helped found in 2006.
Thomas Reynolds	Dr. Thomas C. Reynolds, M.D., Ph.D., is Independent Director of Mei Pharma Inc. Dr. Reynolds served as Chief Medical Officer of Seattle Genetics from March 2007 until his retirement in February 2013. While at Seattle Genetics, he was responsible for building and an integrated clinical development, regulatory and medical affairs organization, highlighted by the development and approval of ADCETRIS®, an antibody-drug conjugate approved to treat anaplastic cell lymphoma and Hodgkin’s lymphoma. Previously, Dr. Reynolds served at ZymoGenetics (acquired by Bristol-Myers Squibb in 2010), most recently as Vice President, Medical Affairs, where he oversaw the clinical development and regulatory filing of RECOTHROM®. Prior to joining ZymoGenetics, he was Vice President, Clinical Affairs at Targeted Genetics. Dr. Reynolds received his M.D. and Ph.D. in Biophysics from Stanford University and a B.A. in Chemistry from Dartmouth College.
William Rueckert	Mr. William D. Rueckert is Independent Director of MEI Pharma, Inc. Mr. Rueckert was previously a director of Marshall Edwards, Inc. between March 2007 and March 2009. Mr. Rueckert has been a director of Novogen since March 2009 and was elected Chairman of the Novogen Board of Directors on October 18, 2010. Mr. Rueckert is the Managing Member of Oyster Management Group LLC an investment fund specializing in community banks. From 1991 to 2006 he was President and Director of Rosow & Company, a private investment firm based in Connecticut. Mr. Rueckert has been President and Director of Eastern Capital Development, LLC from 1999 to 2005, treasurer of Moore & Munger, Inc., a company with interests in the petroleum and resort development industries, from 1988 until 1990, and was President of United States Oil Company, a publicly traded oil exploration business, from 1981 to 1988. Among his many civic associations, Mr. Rueckert is Director and President of the Cleveland H. Dodge Foundation, a private philanthropic organization in New York City, and Chairman of the Board of the Trustees of Teachers College, Columbia University.
Pete De Spain

Basic Compensation

Name	Fiscal Year Total
Daniel Gold	782,000
Thomas Zech	359,051
Robert Mass	151,667
Christine White	--
Charles Baltic	--
Leah Cann	--
Thomas Reynolds	--
William Rueckert	--
Pete De Spain	--

As Of 29 Jun 2012

Options Compensation

Name	Options	Value
Daniel Gold	0	0
Thomas Zech	0	0
Robert Mass	0	0
Christine White	0	0
Charles Baltic	0	0
Leah Cann	0	0
Thomas Reynolds	0	0
William Rueckert	0	0
Pete De Spain	0	0

Insider Trading

Name	Shares Traded	Price
NEW LEAF VENTURES II L P	100,000	$8.45
NEW LEAF VENTURES II L P	100,000	$8.70
NEW LEAF VENTURES II L P	157,300	$8.43
NEW LEAF VENTURES II L P	100,000	$8.57
NEW LEAF VENTURES II L P	300,000	$6.80
NEW LEAF VENTURES II L P	197,225	$6.60
BALTIC CHARLES V III	5,920	$5.90
BALTIC CHARLES V III	4,200	$6.25
BALTIC CHARLES V III	80	$5.75
BALTIC CHARLES V III	800	$6.25
BALTIC CHARLES V III	1,800	$7.19
BALTIC CHARLES V III	1,700	$7.17
NOVOGEN LTD	17,837,246	$0.00
AUSTIN JOSIAH T	3,478,245	$0.00
NOVOGEN LTD	4,827,000	$0.00
BALTIC CHARLES V III	15,000	$0.43
NOVOGEN LTD	4,494,377	$0.89
RUECKERT WILLIAM DODGE	1,417	$0.89
WILLIAMS BRYAN	250	$0.89
NOVOGEN LTD	1,941,747	$1.03
NOVOGEN LTD	1,333,333	$1.50

» Full list on Insider Trading

People: MEI Pharma Inc (MEIP.PH)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: